Guideline for opioid therapy and chronic noncancer pain

CMAJ

Volumn 189, Issue 18, 2017, Pages E659-E666

  Busse, Jason W ^a,b   Craigie, Samantha ^a,c   Juurlink, David N ^a,c   Buckley, D Norman ^b,c   Li, Wang ^a,c   Couban, Rachel J ^a,c   Agoritsas, Thomas ^d   Akl, Elie A ^e   Carrasco Labra, Alonso ^b   Cooper, Lynn ^f,g   Cull, Chris ^h   Da Costa, Bruno R ⁱ   Frank, Joseph W ^j,k   Grant, Gus ^l   Iorio, Alfonso ^m   Persaud, Navindra ⁿ   Stern, Sol ^o   Tugwell, Peter ^p   Vandvik, Per Olav ^q   Guyatt, Gordon H ^c  

^a Institute for Pain Research and Care   (Canada)

^b Department of Anesthesia ^*  (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^e AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^f Canadian Pain Coalition   (Canada)

^g UNIVERSITY OF CHILE   (Chile)

^h Inspire by Example   (Canada)

ⁱ UNIVERSITY OF BERN   (Switzerland)

^j VETERANS AFFAIRS MEDICAL CENTER   (United States)

^k UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^l Nova Scotia Physician Achievement Review Program   (Canada)

^m UNIVERSITY OF TORONTO   (Canada)

ⁿ ST MICHAEL'S HOSPITAL   (Canada)

^o Argus Medical Centre   (Canada)

^p UNIVERSITY OF OTTAWA   (Canada)

^q INNLANDET HOSPITAL TRUST   (Norway)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CODEINE; HYDROMORPHONE; MORPHINE; OPIATE; OXYCODONE; TAPENTADOL; TRAMADOL; NARCOTIC ANALGESIC AGENT;

ADDICTION; ARTICLE; CANADA; CHRONIC NONCANCER PAIN; CHRONIC PAIN; CONSTIPATION; DRUG DOSE TITRATION; DRUG FATALITY; EVIDENCE BASED MEDICINE; HUMAN; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; NAUSEA; OPIATE ADDICTION; PRACTICE GUIDELINE; PRESCRIPTION; RISK ASSESSMENT; SEDATION; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VOMITING; DOSE RESPONSE; DRUG MONITORING; OPIOID-RELATED DISORDERS; PAIN MEASUREMENT; PRIMARY HEALTH CARE; STANDARDS;

ANALGESICS, OPIOID; CHRONIC PAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; HUMANS; OPIOID-RELATED DISORDERS; PAIN MEASUREMENT; PRIMARY HEALTH CARE; TREATMENT OUTCOME;

EID: 85019153936     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.170363     Document Type: Article

References (53)

1. Merskey H, Bogduk N; Task Force on Taxonomy of the International Association for the Study of Pain. Classification of chronic pain, second edition (revised). Seattle (WA): International Association for the Study of Pain; 1994.
2. Reitsma ML, Tranmer JE, Buchanan DM, et al. The prevalence of chronic pain and pain-related interference in the Canadian population from 1994 to 2008. Chronic Dis Inj Can 2011;31:157-64.
3. Hogan ME, Taddio A, Katz J, et al. Health utilities in people with chronic pain using a population-level survey and linked health care administrative data. Pain 2017;158:408-16.
4. Loeser JD. Economic implications of pain management. Acta Anaesthesiol Scand 1999;43:957-9.
5. Lynch ME. The need for a Canadian pain strategy. Pain Res Manag 2011;16:77-80.
6. International Narcotics Control Board. Narcotic drugs: estimated world requirements for 2004, statistics for 2002. New York: United Nations; 2004.
7. International Narcotics Control Board. Availability of internationally controlled drugs: ensuring adequate access for medical and scientific purposes. New York: United Nations; 2016.
8. Murphy Y, Goldner EM, Fischer B. Prescription opioid use, harms and interventions in Canada: A review update of new developments and findings since 2010. Pain Physician 2015;18:E605-14.
9. Fischer B, Nakamura N, Rush B, et al. Changes in and characteristics of admissions to treatment related to problematic prescription opioid use in Ontario, 2004-2009. Drug Alcohol Depend 2010;109:257-60.
10. Kaplovitch E, Gomes T, Camacho X, et al. Sex differences in dose escalation and overdose death during chronic opioid therapy: A population-based cohort study. PLoS One 2015;10:e0134550.
11. Fischer B, Rehm J, Tyndall M. Effective Canadian policy to reduce harms from prescription opioids: learning from past failures. CMAJ 2016;188:1240-4.
12. A province-by-province look at opioid-overdose stats, including fentanyl. Global News 2016 Nov. 17. Available: http://globalnews. ca/news/3072316 /a-province-by-province-look-at-opioid-overdose-stats-including-fentanyl/ (accessed 2017 Apr. 7).
13. Canadian guideline for safe and effective use of opioids for chronic non-cancer pain Canada. Canada: National Opioid Use Guideline Group (NOUGG); 2010.
14. Fernandes K, Martins D, Juurlink D, et al. High-dose opioid prescribing and opioidrelated hospitalization: A population-based study. PLoS One 2016;11:e0167479.
15. Laine C, Taichman DB, Mulrow C. Trustworthy clinical guidelines. Ann Intern Med 2011;154:774-5.
16. Guyatt GH, Oxman AD, Kunz R, et al. Going from evidence to recommendations. BMJ 2008;336:1049-51.
17. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6.
18. Hegmann KT, Weiss MS, Bowden K, et al. ACOEM practice guidelines: opioids for treatment of acute, subacute, chronic, and postoperative pain. J Occup Environ Med 2014;56:e143-59.
19. Manchikanti L, Abdi S, Atluri S, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2-guidance. Pain Physician 2012;15(Suppl):S67-116.
20. Interagency guideline on opioid dosing for chronic noncancer pain: An education aid to improve care and safety with opioid therapy. Olympia (WA): Washington State Agency Medical Directors Group; 2010. Available: www. Agencymeddirectors. wa. gov/Files/OpioidGdline. pdf (accessed 2017 Mar. 9).
21. New York City Department of Health and Mental Hygiene. Preventing misuse of prescription opioid drugs. City Health Information 2011;30:23-30.
22. VA/DoD clinical practice guideline: management of opioid therapy for chronic pain. Washington (DC): Department of Veterans Affairs/Department of Defense; 2010. Available: www. va. gov/painmanagement/docs/cpg-opioidtherapy-fulltext. pdf (accessed 2017 Mar. 9).
23. Akl EA, Sun X, Busse JW, et al. Specific instructions for estimating unclearly reported blinding status in randomized trials were reliable and valid. J Clin Epidemiol 2012;65:262-7.
24. Randolph AG, Cook DJ, Guyatt G. Prognosis. In: Guyatt G, Rennie D, Meade MO, et al., editors. Users' guides to the medical literature: A manual for evidence-based clinical practice. 3rd ed. New York: American Medical Association; 2015:421-9.
25. Andrews J, Guyatt G, Oxman AD, et al. GRADE guidelines: 14. Going from evidence to recommendations: The significance and presentation of recommendations. J Clin Epidemiol 2013;66:719-25.
26. Andrews JC, Schunemann HJ, Oxman AD, et al. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength. J Clin Epidemiol 2013;66:726-35.
27. Guyatt GH, Alonso-Coello P, Schunemann HJ, et al. Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group. J Clin Epidemiol 2016;80:3-7.
28. Vandvik PO, Brandt L, Alonso-Coello P, et al. Creating clinical practice guidelines we can trust, use, and share: A new era is imminent. Chest 2013;144:381-9.
29. Hylan TR, Von Korff M, Saunders K, et al. Automated prediction of risk for problem opioid use in a primary care setting. J Pain 2015;16:380-7.
30. Banta-Green CJ, Merrill JO, Doyle SR, et al. Opioid use behaviors, mentalhealth and pain-development of a typology of chronic pain patients. Drug Alcohol Depend 2009;104:34-42.
31. Colburn JL, Jasinski DR, Rastegar DA. Long-term opioid therapy, aberrant behaviors, and substance misuse: comparison of patients treated by resident and attending physicians in a general medical clinic. J Opioid Manag 2012;8:153-60.
32. Ives TJ, Chelminski PR, Hammett-Stabler CA, et al. Predictors of opioid misuse in patients with chronic pain: A prospective cohort study. BMC Health Serv Res 2006;6:46.
33. Han B, Compton WM, Jones CM, et al. Nonmedical prescription opioid use and use disorders among adults aged 18 through 64 years in the United States, 2003-2013. JAMA 2015;314:1468-78.
34. Fischer B, Argento E. Prescription opioid related misuse, harms, diversion and interventions in Canada: A review. Pain Physician 2012;15(Suppl 3):ES191-203.
35. Dapoigny M, Abitbol JL, Fraitag B. Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study. Dig Dis Sci 1995;40:2244-9.
36. Gana TJ, Pascual ML, Fleming RR, et al. Extended-release tramadol in the treatment of osteoarthritis: A multicenter, randomized, double-blind, placebocontrolled clinical trial. Curr Med Res Opin 2006;22:1391-401.
37. Vorsanger GJ, Xiang J, Gana TJ, et al. Extended-release tramadol (tramadol ER) in the treatment of chronic low back pain. J Opioid Manag 2008;4:87-97.
38. DeLemos BP, Xiang J, Benson C, et al. Tramadol hydrochloride extendedrelease once-daily in the treatment of osteoarthritis of the knee and/or hip: A double-blind, randomized, dose-ranging trial. Am J Ther 2011;18:216-26.
39. Rauck R, Rapoport R, Thipphawong J. Results of a double-blind, placebo-controlled, fixed-dose assessment of once-daily OROS(R) hydromorphone ER in patients with moderate to severe pain associated with chronic osteoarthritis. Pain Pract 2013;13:18-29.
40. Mangel AW, Bornstein JD, Hamm LR, et al. Clinical trial: Asimadoline in the treatment of patients with irritable bowel syndrome. Aliment Pharmacol Ther 2008;28:239-49.
41. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: A cohort study. Ann Intern Med 2010;152:85-92.
42. Baron MJ, McDonald PW. Significant pain reduction in chronic pain patients after detoxification from high-dose opioids. J Opioid Manag 2006;2:277-82.
43. Harden P, Ahmed S, Ang K, et al. Clinical implications of tapering chronic opioids in a veteran population. Pain Med 2015;16:1975-81.
44. Allen MJ, Asbridge MM, Macdougall PC, et al. Self-reported practices in opioid management of chronic noncancer pain: A survey of Canadian family physicians. Pain Res Manag 2013;18:177-84.
45. Chang Y, Zhu KL, Florez ID, et al. Attitudes toward the Canadian guideline for safe and effective use of opioids for chronic non-cancer pain: A qualitative study. J Opioid Manag 2016;12:377-87.
46. Agoritsas T, Heen AF, Brandt L, et al. Decision aids that really promote shared decision making: The pace quickens. BMJ 2015;350:g7624.
47. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain-United States, 2016. MMWR Recomm Rep 2016;65:1-49.
48. College Board adopts new professional standard on safe prescribing to address public health emergency related to opioid overdoses [media release]. Vancouver: College of Physicians and Surgeons of British Columbia; 2016 June Available: www. cpsbc. ca/files/pdf/2016-06-01-Board-Adopts-New-Standard-on-Safe-Prescribing. pdf (accessed 2017 Feb. 11).
49. College endorses the US Centers for Disease Control and Prevention's guidelines for prescribing opioids for chronic pain [media release]. Halifax (NS): College of Physicians & Surgeons of Nova Scotia; 2016. Available: www. cpsns. ns. ca/News/Press-Releases/Details/ArticleId/266/College-Endorses-CDC-Guidelines-for-Prescribing-Opioids-for-Chronic-Pain (accessed 2017 Mar. 11).
50. Busse JW, Juurlink D, Guyatt GH. Addressing the limitations of the CDC guideline for prescribing opioids for chronic noncancer pain. CMAJ 2016;188:1210-1.
51. Kaye AD, Jones MR, Kaye AM, et al. Prescription opioid abuse in chronic pain: An updated review of opioid abuse predictors and strategies to curb opioid abuse (part 2). Pain Physician 2017;20(2S):S111-S133.
52. Nielsen S, Degenhardt L, Hoban B, Gisev N. A synthesis of oral morphine equivalents (OME) for opioid utilisation studies. Pharmacoepidemiol Drug Saf. 2016;25(6):733-7. Available: http://onlinelibrary. wiley. com/doi/10. 1002/pds. 3945/full.
53. Rolfs RT, Johnson E, Williams NJ, Sundwall DN. Utah clinical guidelines on prescribing opioids for treatment of pain. J Pain Palliat Care Pharmacother. 2010;24(3):219-35.